Published in

Wiley, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 6(11), p. 658-671, 2014

DOI: 10.1016/j.jalz.2014.05.1757

Links

Tools

Export citation

Search in Google Scholar

Convergent genetic and expression data implicate immunity in Alzheimer's disease

Journal article published in 2014 by Maria del Zompo, Renee F. A. G. de Bruijn, Jean-Charles Lambert, Cornelia M. van Duijn, Li-San Wang, Thornton Wells Ta, Lesley Jones, Alexey Vedernikov, Dunstan Ml, Denise Harold, Timothy Stone, Crane Pk, Alexander Richards, Valentina Escott-Price ORCID, Adam C. Naj and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

© 2015, Elsevier Inc. All rights reserved. Background: Late-onset Alzheimer's disease (AD) is heritable with 20 genes showing genome-wide association in the International Genomics of Alzheimer's Project (IGAP). To identify the biology underlying the disease, we extended these genetic data in a pathway analysis. Methods: The ALIGATOR and GSEA algorithms were used in the IGAP data to identify associated functional pathways and correlated gene expression networks in human brain. Results: ALIGATOR identified an excess of curated biological pathways showing enrichment of association. Enriched areas of biology included the immune response (P = 3.27 × 10 -12 after multiple testing correction for pathways), regulation of endocytosis (P = 1.31 × 10 -11 ), cholesterol transport (P = 2.96 × 10 -9 ), and proteasome-ubiquitin activity (P = 1.34 × 10 -6 ). Correlated gene expression analysis identified four significant network modules, all related to the immune response (corrected P =.002-.05). Conclusions: The immune response, regulation of endocytosis, cholesterol transport, and protein ubiquitination represent prime targets for AD therapeutics. ; Medical Research Council, Alzheimer’s Research UK, and theWelsh Assembly Government. ADGC and CHARGE were supported by the National Institutes of Health, National Institute on Aging (NIH-NIA). CHARGE was also supported by Erasmus Medical Center and Erasmus University. IGAP was funded by the French National Foundation on Alzheimer’s Disease and Related Disorders, the Centre National de Genotypage and the Institut Pasteur de Lille, Inserm, FRC (Fondation pour la Recherche sur le Cerveau), and Rotary. This work has been developed and supported by the LABEX (Laboratory of Excellence Program Investment for the Future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer’s disease). ; Peer Reviewed